Drugs in ATC Class B05AA

Up to Top Level ATC Classes

Up to B - Blood and blood forming organs

Up to B05 - BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS

Up to B05A - BLOOD AND RELATED PRODUCTS

Drugs in ATC Class: B05AA - Blood substitutes and plasma protein fractions

Tradename	Generic Name
OPTISON	albumin human
DEXFERRUM	iron dextran
INFED	iron dextran
IRON DEXTRAN	iron dextran
PROFERDEX	iron dextran

Last updated: June 28, 2026

ATC Class B05AA Blood substitutes and plasma protein fractions: market dynamics and patent landscape

Executive summary: ATC B05AA spans multiple biologics and blood-substitute products, with exclusivity and patent risk driven by (1) whether the product is a plasma protein fraction (human-derived) versus a synthetic/alternative blood substitute, (2) manufacturing-process claims, and (3) jurisdiction-specific regulatory exclusivity. Patent estates tend to cluster around formulation, purification steps, stabilization/excipients, and method-of-use. Commercial dynamics hinge on supply reliability, hospital formularies, and procurement contracting, with biosimilar-type competition mainly relevant where the FDA pathway and reference biologics allow it.

Important limitation: A complete, product-by-product patent landscape requires the specific active ingredients and reference-listed products within ATC B05AA (e.g., which plasma protein fraction(s) and which blood substitutes are in scope). Without that scope, any numbered patent list or timeline would risk being incomplete or incorrect.

What is ATC Class B05AA and which products sit inside it?

ATC B05AA is labeled for “Blood substitutes and plasma protein fractions.” In practice, the class can include multiple distinct therapeutic modalities:

• Plasma protein fractions derived from human plasma (for example, albumin and other plasma-derived proteins where listed under B05A).
• Other blood substitutes (synthetic or alternative solutions) used to maintain circulating volume and/or oncotic pressure in acute settings.

From a patent and market perspective, B05AA is best treated as a basket of products with different IP profiles:

• Plasma-derived proteins: strong process-and-purification patenting, donor management and fractionation workflows, viral inactivation steps, and formulation/stabilization. Market entry is constrained by plasma supply, regulatory quality systems, and manufacturing scale.
• Synthetic blood substitutes: more emphasis on composition of matter and formulation (stability, osmolality, particle size for colloids where applicable), with second-generation improvements creating incremental patent layers.

How do regulators define the product boundary (biologic vs drug) for B05AA?

The regulatory classification determines the IP attack surface:

• Biologic/plasma-derived: exclusivity and biosimilar pathways govern competition risk; patent litigation often centers on manufacturing and analytical comparability rather than only formulation.
• Small-molecule/solution drugs: generic competition can target ANDA-style substitution and may attack formulation/manufacturing claims only.

What market dynamics drive pricing and procurement for blood substitutes and plasma protein fractions?

Hospital demand drivers

• Acute use cycles (trauma, surgery, ICU volume resuscitation, burn care, and hospital perioperative protocols) drive inventory planning rather than chronic dosing.
• Risk management and protocol adherence affect formulary placement and switching.

Supply-side constraints

• Plasma fraction products depend on donor availability and fractionation capacity. That supply bottleneck shapes realized margins and reduces substitution speed even when patent barriers loosen.
• Regulatory and quality systems create lead time for new entrants, increasing the commercial value of incumbents during exclusivity gaps.

Contracting

• Tender-based procurement and multi-year contracting reduce price volatility but also increase switching friction. Patent “expiry” does not automatically trigger rapid market share shifts.

How many patents cover B05AA products and what claim types dominate?

B05AA estates usually show high density in:

1. Process patents
   • Fractionation and purification chromatography
   • Viral inactivation validation steps (heat, low pH, solvent/detergent where applicable depending on product type)
   • Filtration, concentration, and diafiltration
2. Formulation and stabilization patents
   • pH adjustment, buffering systems
   • Stabilizers to limit aggregation
   • Compatibility with infusion devices and container materials
3. Method-of-use patents
   • Specific clinical endpoints (e.g., perioperative volume goals or patient subsets)
   • Administration regimens and infusion parameters

Where the product is plasma-derived, “composition of matter” is often less defensible than process and formulation, because the active substance is defined by biological source and known characterization. Incumbents instead build layered IP around how it is made and stabilized.

Which patents protect plasma protein fractions in ATC B05AA?

Typical protected subject matter

• Fractionation method claims (upstream/downstream steps)
• Viral safety assurance steps tied to validated process parameters
• Formulations specifying excipient systems and concentration ranges
• Container/sterile filtration compatibility

Patent landscape pattern

• Fragmented jurisdiction: U.S., EP, and key national routes carry different claim strategies. EP and national filings often emphasize purification and viral inactivation as narrower but enforceable claims, while U.S. filings may have broader process coverage plus method-of-use.

Which patents protect blood substitutes in ATC B05AA?

For synthetic or non-plasma blood substitutes, patent estates more frequently include:

• Compositions for volume expansion and osmolality control
• Stabilization for storage and infusion (anti-aggregation, dispersion stability)
• Manufacturing methods for consistent physicochemical properties (particle size, molecular weight distribution)

What is the Orange Book status of B05AA products, and how does it affect generic entry?

Orange Book relevance depends on whether the product is listed as:

• Therapeutic biological product (Orange Book may be limited or absent)
• Approved drug product with ANDA pathways (Orange Book is critical)

For each B05AA member, the generic risk is driven by:

• Listed patents (drug substance, formulation, and method-of-use where applicable)
• Exclusivity codes (including data exclusivity and marketing exclusivity that can block ANDA approval timelines)

A reliable Orange Book-based timeline cannot be generated without the specific reference products within B05AA.

When does exclusivity end for blood substitutes and plasma protein fractions in ATC B05AA?

Exclusivity is usually layered:

• Regulatory exclusivity (data and marketing exclusivity under FDA rules)
• Patent term (including adjusted patent expiration)
• Paediatric and supplemental exclusivity (where applicable for certain biologics/drugs)
• Patent “last-to-expire” effect because FDA approval can be delayed by infringement risks tied to listed patents

In hospital procurement, even when exclusivity ends, the incumbent can retain share if:

• the entrant faces supply ramp constraints,
• clinicians resist switching,
• or clinical contracting favors the incumbent.

What Paragraph IV challenges exist for ATC B05AA products?

Paragraph IV is relevant when:

• a reference-listed drug has Orange Book patents suitable for certification, and
• an ANDA filer seeks approval before patent expiry.

For plasma protein fractions and other biologics, competition often shifts to biosimilar pathways instead of Paragraph IV as the primary entry model, depending on regulatory classification.

A definitive count of Paragraph IV cases cannot be produced without enumerating the specific B05AA reference products in scope.

What biosimilar and interchangeability risks affect B05AA?

Biosimilar risk depends on:

• Whether the product is considered a biologic with a biosimilar pathway in the U.S.
• Whether an approved biosimilar can obtain licensure using comparability to a reference product.
• Whether patent coverage includes claims strong enough to block biosimilar approval.

For plasma-derived proteins, biosimilar-like competition is constrained by:

• donor source variability,
• purification workflow control,
• and analytical comparability requirements.

How does patent strength compare across plasma-derived versus synthetic blood substitutes?

Plasma-derived:

• Strength often comes from process and viral inactivation validation claims.
• Switching cost is high because supply and manufacturing controls matter.

Synthetic blood substitutes:

• Strength more often comes from formulation and composition-related claims.
• If composition claims are narrow or earlier art dominates, entry can accelerate once regulatory barriers lift.

Which companies are positioned to compete in B05AA when patents expire?

Competition in this class typically comes from:

• incumbent manufacturers of plasma-derived fractions with large-scale purification plants,
• biosimilar and plasma-derivative specialists for biologics-like entries,
• synthetic blood substitute manufacturers for alternative formulations.

A defensible competitor list requires the exact B05AA active ingredients and their labeled U.S./EU reference products to map to known challengers and litigants.

What patent litigation affects blood substitutes and plasma protein fractions?

Litigation themes typically include:

• process patent infringement (purification and viral inactivation)
• formulation stabilization (excipient systems and concentration windows)
• method-of-use (clinical regimen adherence)
• enforceability challenges tied to obviousness and written description

Settlement agreements in this space often include:

• “launch-at-risk” limitations,
• licensing with fixed market entry dates,
• and supply or exclusivity-like arrangements tied to regulatory approvals.

A litigation chronology cannot be populated without identifying the specific patent families and product references in ATC B05AA.

What do licensing and settlement agreements look like for B05AA?

Where settlements occur, they tend to:

• define a non-infringing formulation or process design-around,
• specify an entry date tied to patent expiry,
• and establish royalties or covenants.

For plasma-derived products, settlements can also reflect supply agreements because entrants need plasma procurement capacity and validation timelines.

How does B05AA compare with adjacent ATC classes on IP and competition risk?

Compared with other blood and coagulation-related classes, B05AA has:

• higher supply-manufacturing interdependence for plasma-derived products,
• and more process-centric patent estates.

Adjacent categories often show different IP patterns:

• coagulation factor products: heavier method-of-use and sequence-related IP (for recombinant biologics),
• iron and erythropoiesis agents: composition and production cell-line/process for biologics or formulation for small molecules.

Patent estate mapping framework for ATC B05AA (how to structure due diligence)

Use this framework for each B05AA reference product:

1. Identify active ingredient(s) and dosage forms
2. Map FDA and EMA reference products
3. Extract listed patents and exclusivity from relevant regulatory databases
4. Cluster patents by claim scope
   • composition, formulation, process, and method-of-use
5. Assess litigation and licensing history
6. Identify likely design-arounds
   • alternative viral inactivation method, excipient changes, chromatographic conditions
7. Translate patent expiry into commercial entry scenarios
   • immediate launch, delayed settlement launch, launch-at-risk, or biosimilar rollout with additional clinical work

Key Takeaways

• ATC B05AA is an IP-diverse class where the dominant patent risk typically shifts between process/formulation (plasma-derived proteins) and composition/formulation (synthetic substitutes).
• Market competition is constrained not only by patents and exclusivity, but also by plasma supply and manufacturing validation lead times for plasma protein fractions.
• Due diligence should prioritize process/viral inactivation claims and formulation stabilization claims, which often represent the enforceable core of B05AA estates.
• Patent and litigation timelines cannot be reliably quantified without the specific B05AA reference products (active ingredients, dosage forms, and their FDA/EMA listings).

FAQs

1. Which types of patents most often block generic or biosimilar competition for plasma protein fractions?
2. How do viral inactivation and purification process claims affect design-around strategies?
3. What regulatory exclusivity layers typically delay approval even after patent expiration?
4. How do hospital formularies and tender contracts influence the speed of market entry post-exclusivity?
5. What commercial indicators signal an impending competitive entry for blood substitutes and plasma protein fractions?

References

1. European Medicines Agency. ATC classification and product information. (EMA website).
2. U.S. Food and Drug Administration. Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. (FDA website).
3. U.S. Food and Drug Administration. Biological License Application (BLA) and biosimilar pathway guidance documents. (FDA website).